LGALS3 and diffuse large B-cell lymphoma: The Gal-3 antagonist named GCS-100 is a MCP, capable of binding to and antagonizing Gal-3, developed (La Jolla Pharmaceutical Company, San Diego, CA, USA) and utilized in a clinical trial (ClinicalTrials.gov Identifier: NCT00776802) for the treatment of refractory diffuse large B-cell lymphoma and refractory solid tumors [396].